“Project Recode” aims to make human cells invulnerable to infection
A genome-writing consortium announced today that it intends to revise the genome of human cells in the lab so they resist viruses.
What’s recoding? A person’s genome uses three-letter “codons” (think AGT or CAT) to direct the assembly of proteins. But it turns out there are extra codons that aren’t needed. The plan is simple: get rid of them. That’s going to take some heavy-duty gene editing—more than 400,000 changes to about 20,000 human genes.
Who’s behind it: The project is the first big announcement by GP-Write, a private organization trying to hurry us up to the point where we can easily print human genomes. So far it lacks serious funding, but a gene-editing company, Cellectis, says it will donate its technology to the cause. The effort is expected to take about a decade.
Bad for viruses: Viruses use the missing codons to propagate in cells, so a recoded cell would be essentially virus-proof. The researchers say such “ultra-safe” cells could be good for the biotech industry, which uses human cells to manufacture drugs.
Are virus-proof people coming? That’s certainly a possibility, according to project leader George Church of Harvard Medical School. He once wrote that recoded humans would be the “climax” of synthetic biology.
Deep Dive
Biotechnology and health
How scientists traced a mysterious covid case back to six toilets
When wastewater surveillance turns into a hunt for a single infected individual, the ethics get tricky.
An AI-driven “factory of drugs” claims to have hit a big milestone
Insilico is part of a wave of companies betting on AI as the "next amazing revolution" in biology
The quest to legitimize longevity medicine
Longevity clinics offer a mix of services that largely cater to the wealthy. Now there’s a push to establish their work as a credible medical field.
There is a new most expensive drug in the world. Price tag: $4.25 million
But will the latest gene therapy suffer the curse of the costliest drug?
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.